Evidence map›Paper›PMID 20440286›Full record

ReviewNature reviews. Rheumatology2010

Using genetics to deliver personalized SLE therapy-a realistic prospect?

Benjamin Rhodes, Timothy J Vyse

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Benjamin RhodesRheumatology Section, Division of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK.
Timothy J Vyse
Imperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Staggering advances have been made in our understanding of the genetic basis of human systemic lupus erythematosus (SLE), but has this been sufficient to fulfill early predictions that we could use genetics to provide personalized healthcare? Our current understanding of the genetic etiology of SLE indicates a strong underlying genetic predisposition, mediated by multiple gene variants. Compared with other complex genetic diseases, the disease risk imparted by many of these variants is strong. We argue that, for SLE, this particular combination of genetic effects means that the personalized prediction of disease onset or manifestation is certainly a realistic possibility, although further large-scale genetic studies will be required before this becomes a reality. We speculate that, in the future, genetic information could help guide targeted therapeutic intervention.

Indexed as

Gene Expression ProfilingGenetic Predisposition to DiseaseHumansLupus Erythematosus, SystemicPrecision MedicinePredictive Value of TestsRisk Factors

Identifiers

PMID20440286
OpenAlexW2000138729

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.